Can't find Capivasertib (Truqap) in stock? Use these tools and tips to locate a specialty pharmacy that has it and get your prescription filled faster.
When your oncologist prescribes Capivasertib (brand name Truqap), you expect to start treatment quickly. But for many patients with HR-positive, HER2-negative metastatic breast cancer, finding this specialty medication can feel like an uphill battle.
The good news? Capivasertib is not in a true drug shortage. The delays most patients experience come from insurance logistics, specialty pharmacy requirements, and the high cost of the medication. With the right tools and approach, you can cut through these barriers and find Capivasertib in stock.
Here are three practical strategies to help you get your medication faster.
Medfinder is a free tool that helps patients locate medications that are hard to find. Instead of calling pharmacy after pharmacy, you can search for Capivasertib and see which specialty pharmacies currently have it in stock or can fill your prescription quickly.
Here's how to use it:
This can save you hours of phone calls and guesswork. For a detailed walkthrough, see our guide on how to check if a pharmacy has Capivasertib in stock.
Unlike medications you pick up at a retail pharmacy, Capivasertib is dispensed through specialty pharmacies — pharmacies that handle complex, high-cost medications. Your insurance plan may have a preferred specialty pharmacy, but you're not always limited to just one option.
Here's what to do:
Some specialty pharmacies process orders faster than others. If you're experiencing delays with one, switching to another in-network pharmacy may shave days or even weeks off your wait.
Once you've filled your first prescription, staying ahead of refills is critical. Capivasertib is taken on a 4-days-on, 3-days-off schedule, and each 28-day cycle requires 64 tablets. Specialty pharmacies often need lead time to process refills.
Tips for staying on schedule:
Running out of Capivasertib mid-treatment can disrupt your care, so planning ahead is one of the most important things you can do.
If you've tried these steps and are still hitting walls, here are additional options:
AstraZeneca's support program can help coordinate your prescription, navigate insurance issues, and connect you with a specialty pharmacy. Call 844-275-2360 or visit MyAccess360.com.
While Capivasertib is a first-in-class AKT inhibitor, there are other medications that target similar pathways. Alpelisib (Piqray), Everolimus (Afinitor), and Elacestrant (Orserdu) may be options depending on your specific cancer type and mutation status. Learn more in our article on alternatives to Capivasertib.
Cost barriers can also delay access. If affordability is an issue, the Truqap Co-Pay Savings Program may reduce your costs to $0 per month for commercially insured patients. Uninsured patients may qualify for the AZ&Me Patient Assistance Program, which provides Truqap at no cost. For more details, read our guide on saving money on Capivasertib.
If you're being treated at a smaller oncology practice, your doctor may have less experience with the Truqap prescribing process. A breast cancer specialist or oncologist at a larger cancer center may be able to get the drug dispensed more efficiently. See our article on how to find a doctor who can prescribe Capivasertib.
Finding Capivasertib doesn't have to be a mystery. The key is using the right tools — like Medfinder — and being proactive about insurance approvals, refill timing, and pharmacy options. You deserve timely access to your cancer treatment, and with a little preparation, you can make it happen.
For more information about Capivasertib, including how it works and what side effects to expect, explore our other guides:
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
